About C4 Therapeutics, Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://c4therapeutics.com/
Frequently Asked Questions
What is the 52-week range for CCCC?
The 52-week high is $5.17 and the 52-week low is $1.6901.
What is the P/E ratio for CCCC?
The P/E ratio data is currently unavailable.
What is the dividend yield for CCCC?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -45.45%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -289.44%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.72.
Analyst Recommendation Trends
Wall Street analyst consensus for CCCC over the last few months:
Latest CCCC News
PepsiCo, Delta Lead Upcoming Earnings Slate; Fed Minutes In Focus
Preview next weekâs key market eventsâPMI, Fed minutes, jobless claimsâand top earnings (PepsiCo, Delta). Read here for more details.
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of Action Biomarker Data from First Two Patients in Phase 1b Trial of Cemsidomide with Elranatamab Reinforce Cemsidomide’s Ability to Drive T-cell Expansion and Activation, and Prevent T-cell Exhaustion When Combined with Immune-based Therapies First Cemsidomide Dose Level (75 µg) in Phase 1b Trial with Elranatamab Declared Safe by S
C4 Therapeutics Presents New Biomarker Data From Phase 1 Clinical Trial Of Cemsidomide In Combination With Dexamethasone In Patients With RRMM At 23rd IMS Annual Meeting
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of ActionBiomarker Data from First Two Patients in
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and MacroGenics (MGNX) have performed compared to their sector so far this year.
C4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide Readouts
C4 Therapeutics is a clinical-stage biopharmaceutical company that is pre-commercial but brings in revenue through partnerships. Read why CCCC stock is a hold.
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 trial for relapsed/refractory multiple myeloma (RRMM) will be presented in a poster at the 23rd IMS Annual Meeting. The data characterize the immune effect
C4 Therapeutics To Present New Biomarker Data On Immunomodulatory Effects Of Cemsidomide In Combination With Dexamethasone From Phase 1 Trial For RRMM At IMS Annual Meeting
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the immunomodulatory
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-18 | Adams Kendra | -2,775 | $3.39 | $9,407 |
| 2026-09-18 | Adams Kendra | +6,250 | - | - |
| 2026-07-10 | REYNO LEONARD | -7,397 | $4.06 | $30,032 |
| 2026-07-10 | REYNO LEONARD | +15,325 | - | - |
| 2026-07-01 | GROGAN DONNA ROY | +3,341 | $4.34 | $14,500 |
| 2026-07-01 | Anderson Kenneth Carl | +2,650 | $4.34 | $11,501 |
| 2026-06-24 | Koppikar Utpal | +62,000 | - | - |
| 2026-06-24 | Anderson Kenneth Carl | +62,000 | - | - |
| 2026-06-24 | Cooper Ronald Harold Wilfred | +62,000 | - | - |
| 2026-06-24 | Bessen Laura | +62,000 | - | - |
| 2026-06-24 | Fawell Stephen | +62,000 | - | - |
| 2026-06-24 | GROGAN DONNA ROY | +62,000 | - | - |
| 2026-06-24 | Hughes Owen | +62,000 | - | - |
| 2026-06-24 | Hoerter Steven L. | +62,000 | - | - |
| 2026-06-01 | Anderson Kenneth Carl | -1,070 | - | - |
| 2026-06-01 | Anderson Kenneth Carl | +1,070 | $2.11 | $2,258 |
| 2026-04-01 | Anderson Kenneth Carl | +4,259 | $2.7 | $11,499 |
| 2026-04-01 | GROGAN DONNA ROY | +5,370 | $2.7 | $14,499 |
| 2026-02-15 | Hirsch Andrew | -9,057 | $1.89 | $17,118 |
| 2026-02-15 | Hirsch Andrew | +20,400 | - | - |
| 2026-02-14 | Boyle Scott N | -7,269 | $1.89 | $13,738 |
| 2026-02-14 | Boyle Scott N | +20,950 | - | - |
| 2026-02-14 | Mahaney Paige | -2,446 | $1.89 | $4,623 |
| 2026-02-14 | Mahaney Paige | +7,050 | - | - |
| 2026-02-14 | Schick Kelly | -7,269 | $1.89 | $13,738 |
| 2026-02-14 | Schick Kelly | +20,950 | - | - |
| 2026-02-14 | Adams Kendra | -15,381 | $1.89 | $29,070 |
| 2026-02-14 | Adams Kendra | +30,950 | - | - |
| 2026-02-14 | Mossler Mark | -3,268 | $1.89 | $6,177 |
| 2026-02-14 | Mossler Mark | +9,420 | - | - |
| 2026-02-14 | Hirsch Andrew | -39,154 | $1.89 | $74,001 |
| 2026-02-14 | Hirsch Andrew | +81,725 | - | - |
| 2026-02-14 | REYNO LEONARD | -16,579 | $1.89 | $31,334 |
| 2026-02-14 | REYNO LEONARD | +30,950 | - | - |
| 2026-02-13 | Boyle Scott N | -1,735 | $1.89 | $3,279 |
| 2026-02-13 | Boyle Scott N | +5,000 | - | - |
| 2026-02-13 | Boyle Scott N | +200,000 | - | - |
| 2026-02-13 | Mahaney Paige | +240,000 | - | - |
| 2026-02-13 | Schick Kelly | -1,735 | $1.89 | $3,279 |
| 2026-02-13 | Schick Kelly | +5,000 | - | - |
| 2026-02-13 | Schick Kelly | +200,000 | - | - |
| 2026-02-13 | Adams Kendra | -1,863 | $1.89 | $3,521 |
| 2026-02-13 | Adams Kendra | +3,750 | - | - |
| 2026-02-13 | Adams Kendra | +240,000 | - | - |
| 2026-02-13 | Mossler Mark | +56,980 | - | - |
| 2026-02-13 | Hirsch Andrew | +700,000 | - | - |
| 2026-02-13 | REYNO LEONARD | +240,000 | - | - |
| 2026-01-16 | REYNO LEONARD | -10,000 | $2.22 | $22,200 |
| 2026-01-02 | Anderson Kenneth Carl | +5,958 | $1.93 | $11,499 |
| 2026-01-02 | GROGAN DONNA ROY | +7,513 | $1.93 | $14,500 |
| 2025-10-28 | Mahaney Paige | -5,644 | $2.58 | $14,562 |
| 2025-10-28 | Mahaney Paige | +19,200 | - | - |